Insider Buying Spurs Optimism in a Volatile Stock The latest Form 4 filed on October 2, 2026 shows Novel Inspiration International Co., Ltd. (Novel Inspiration) adding 146,313 shares of IRIDEX Corporation to its position, bringing its holdings to 697,742 shares. This purchase comes at a price of $0.93 per share, the same as the closing price on October 11, and occurs amid a 36.62 % weekly rally and 45.16 % monthly gain for the stock. The move is notable because it follows a series of incremental acquisitions by Novel Inspiration that have steadily increased its stake from 97,610 shares in October 2025 to nearly 700,000 shares today.
What This Means for Investors IRIDEX’s share price has rebounded strongly from a 12.36 % yearly decline, but its market cap remains modest at $15.63 million and its trailing P/E is negative, indicating limited profitability. In this context, the continued buying by a foreign investor who has previously been a passive holder suggests confidence in the company’s long‑term growth prospects. For investors, this could be interpreted as a signal that IRIDEX may be poised for a breakout once its new laser‑based therapies gain regulatory traction, or that the company’s valuation is still undervalued relative to its product pipeline. However, the low share price also means that a single insider purchase can create significant volatility, so traders should monitor the volume and price action closely.
Novel Inspiration’s Historical Buying Pattern Novel Inspiration’s transaction history with IRIDEX shows a clear, gradual accumulation strategy. Beginning with a 97,610‑share purchase in October 2025, the investor added 111,997 shares in July 2026 and 87,949 shares in April 2026, culminating in the latest 146,313‑share purchase. The total position grew from roughly 100,000 shares to nearly 700,000 shares in a little over a year. This disciplined accumulation, without any large sales, indicates a long‑term investment thesis rather than a short‑term trading play. The investor’s consistent buying at a wide range of prices—often below the 52‑week low—suggests a belief that IRIDEX’s stock is undervalued and has room for upside.
Insider Activity Beyond Novel Inspiration Other insiders, such as CEO Mercer Patrick and CFO Dizon Romeo, have also been active in recent months, buying and selling in the tens of thousands of shares. Their trades, however, are more scattered and often involve options or performance‑restricted units, reflecting typical executive compensation structures. The absence of large sell‑offs from key insiders strengthens the narrative that core management remains confident in IRIDEX’s future.
Bottom Line for the Market With IRIDEX’s share price rallying and a foreign investor steadily piling into the stock, the market may view this as a green light for further upside. The company’s niche technology in ophthalmology and dermatology, combined with a modest valuation, could attract value investors looking for high‑growth biotech plays. As always, the low price and negative P/E warrant caution—investors should pair this insider buying signal with fundamentals, regulatory updates, and earnings guidance before committing capital.
| Date | Owner | Transaction Type | Shares | Price per Share | Security |
|---|---|---|---|---|---|
| 2026-10-02 | Novel Inspiration International Co., Ltd. () | Buy | 146,313.00 | N/A | Common Stock |
